Great MM015 news just out-Revlimid increases QofL (Velcade decreases)
BMO Capital Markets - Celgene Target: $143.00 Outperform
Published QOL Data From MM-015 Supports Revlimid Frontline - The improvement in QoL observed during induction was maintained during maintenance and at cycle 16 of Revlimid.
Flash: MM-015 investigators published a review of health-related quality of life (QoL) data from the MM-015 trial for Celgene's (CELG) Revlimid as frontline maintenance therapy in transplant ineligible patients with multiple myeloma in the May issue of the journal Hematologica (Dimopoulos et al.).
A comparison of QoL changes between MP and MPR-R cohorts using both the global QLQ-30 and myeloma-specific QLQ-MY20 tools was a pre-defined secondary endpoint of the MM-015 trial. During induction, global QoL improved 12.2 points in the MPRR cohort compared with 6.2 points in the MP cohort (p
The improvement in QoL observed during induction was maintained during maintenance and at cycle 16 of Revlimid.
All QoL domains were statistically significantly improved over baseline except side effects from treatment, which was not different from baseline. Clinically meaningful differences were more frequently observed in patients receiving MPR-R than MP, especially for physical functioning.
o We think achievement of a clinically meaningful improvement in QoL favoring MPR-R over MP in the MM-015 trial is important from both a commercial and regulatory perspective and supports use of Revlimid in the transplant-ineligible population.
o An amplification of the favorable Revlimid QoL signal in patients aged 65-75 years supports CELG’s focus on this subset of patients for the MM-015-based regulatory filings.
o In Europe, Velcade, combined with MP, is a standard of care for the elderly nontransplant- eligible myeloma population; however, QoL scores were documented to decrease in the first four cycles of induction in the VISTA trial clearly in contrast to the addition of Revlimid to MP in MM-015.